An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Latest Information Update: 26 Dec 2024
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors Acerta Pharma
- 20 Sep 2023 Planned End Date changed from 31 Dec 2025 to 1 Apr 2026.
- 09 Nov 2020 Planned End Date changed from 18 Jun 2025 to 31 Dec 2025.
- 14 Jul 2020 Planned End Date changed from 31 Dec 2019 to 18 Jun 2025.